- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01383694
Effect Of Piperine In Patients With Oropharyngeal Dysphagia (FIS 2009_2)
February 27, 2015 updated by: Pere Clave, Hospital de Mataró
Effect of Natural Agonists of TRPV1 in the Treatment of Functional Oropharyngeal Dysphagia in Neurological Diseases and the Elderly: Piperine
Piperine acts on the oropharyngeal TRPV1, increasing sensory input and the release of substance P.
These actions may accelerate the oropharyngeal swallow response, improving the swallowing of dysphagic patients.
Study Overview
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Barcelona
-
Mataró, Barcelona, Spain, 08304
- Hospital de Mataró
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age>18
- History of swallowing difficulties associated with aging and/or neurological diseases (neurodegenerative or non-progressive neurological diseases)
- Study explained and written subject information given
- Informed consent signed
Exclusion Criteria:
- Patients suffering idiosyncratic phenomena or who are allergic to any medication, especially iodinated contrast media
- Patients suffering major respiratory disease or undergoing any type of surgery in the three months prior to the study
- Patients with a background of alcohol dependence or other drug dependence
- Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Piperine Dose 1
Piperine 1 mM
|
|
|
Experimental: Piperine Dose 2
Piperine 150 microM
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety of swallow
Time Frame: 15 minutes
|
Prevalence of penetrations at the laryngeal vestibule
|
15 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of swallow
Time Frame: 15 minutes
|
Prevalence of oral and pharyngeal residue
|
15 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2011
Primary Completion (Actual)
February 1, 2012
Study Completion (Actual)
February 1, 2012
Study Registration Dates
First Submitted
June 27, 2011
First Submitted That Met QC Criteria
June 27, 2011
First Posted (Estimate)
June 28, 2011
Study Record Updates
Last Update Posted (Estimate)
March 3, 2015
Last Update Submitted That Met QC Criteria
February 27, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FIS 22/09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Deglutition Disorders
-
Centro Hospitalar de Entre o Douro e VougaAveiro UniversityCompletedDeglutition Disorders | DeglutitionPortugal
-
Boston Children's HospitalWithdrawnBottle Feeding | Deglutition Disorders in Infants
-
University of NebraskaCompletedDeglutition DisorderUnited States
-
Ulsan University HospitalWithdrawnDeglutition DisorderKorea, Republic of
-
Ulsan University HospitalWithdrawnDeglutition DisorderKorea, Republic of
-
National Institute of Neurological Disorders and...Completed
-
National Institutes of Health Clinical Center (CC)Completed
-
National Institutes of Health Clinical Center (CC)Completed
-
Baylor College of MedicineRecruitingEsophageal Motility Disorders | AchalasiaUnited States
Clinical Trials on Piperine
-
Universitas DiponegoroDr. Kariadi Hospital Semarang, indonesiaCompletedMalondialdehyde | ST Elevation Myocardial Infarction (STEMI) | Hs-CRP | High-sensitivity C-reactive Protein | Curcumin | Curcuma XanthorrhizaIndonesia
-
Hospital de MataróInstituto de Salud Carlos III; Consorci Sanitari del MaresmeRecruitingStroke | Oropharyngeal Dysphagia | Stroke, Acute | Swallowing DisorderSpain
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedFocus of the Study: Normal VolunteersUnited States
-
University of RochesterCompletedMultiple Myeloma | Prostate Cancer | Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma (SMM)United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedPain | Malignant Neoplasm | Urinary Urgency | Bladder SpasmUnited States
-
National Institute of CancerologíaSabinsa CorporationRecruiting
-
Denise MafraCompleted
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingPolycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myelodysplastic Syndrome | Clonal Cytopenia of Undetermined SignificanceUnited States
-
Hospital de MataróNot yet recruitingOropharyngeal Dysphagia | Swallowing DisorderSpain
-
Hadassah Medical OrganizationCompleted